Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about LEXX
Recent news which mentions LEXX
< Previous
1
2
3
4
Next >
Lexaria Bioscience (NASDAQ: LEXX) Announces Positive Results From Hypertension Study
April 18, 2022
Tickers
LEXX
Tags
Penny Stocks
Benzinga
General
From
Benzinga
51 Biggest Movers From Thursday
April 18, 2022
Tickers
AIRG
AMST
APCX
AREB
Tags
PHAS
HUSA
FRGE
From
Benzinga
Why Is Lexaria Bioscience (LEXX) Stock Up Today?
April 14, 2022
Tickers
LEXX
Tags
NASDAQ:LEXX
Market News
Today's Market
From
InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
April 14, 2022
Tickers
BFRI
CLRB
HSTO
ISO
Tags
Benzinga
LIXT
ISO
From
Benzinga
Why Lexaria Shares Are Rising Today
April 14, 2022
Tickers
LEXX
Tags
Biotech
Market News
Health Care
From
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Issues Update On Human Nicotine Study
April 13, 2022
Tickers
LEXX
LEXXW
Tags
Market News
Partner Content
Biotech
From
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Begins Nicotine Formulation Creation, Evaluation Program
April 12, 2022
Tickers
LEXX
Tags
Penny Stocks
General
News
From
Benzinga
Lexaria Aims To Demonstrate DehydraTECH's Performance In Epilepsy Research
April 11, 2022
Tickers
LEXX
Tags
Benzinga
General
LEXX
From
Benzinga
Lexaria Bioscience's 24th Patent Sets Stage For Market Opportunities In Australia
March 31, 2022
Tickers
LEXX
Tags
InvestorBrandNetwork
Penny Stocks
Benzinga
From
Benzinga
Lexaria Bioscience Optimistic About Upcoming Hypertension Study
March 28, 2022
Tickers
LEXX
Tags
Benzinga
General
Penny Stocks
From
Benzinga
Lexaria's IP Portfolio Grows Following Receipt Of 24th Granted Patent
March 22, 2022
Tickers
LEXX
Tags
Penny Stocks
General
Benzinga
From
Benzinga
Lexaria Bioscience Commences DehydraTECH-CBD Epilepsy Research Program
March 16, 2022
Tickers
LEXX
LEXXW
Tags
Biotech
LEXX
Market News
From
Benzinga
Lexaria Bioscience Receives Award For Oral Nicotine Compound Patent
March 09, 2022
Tickers
LEXX
Tags
LEXX
Biotech
Partner Content
From
Benzinga
Studies Advance Lexaria Bioscience's Tech For Improving Pharmaceutical Drugs
March 07, 2022
Tickers
LEXX
Tags
Market News
Partner Content
Biotech
From
Benzinga
Lexaria's DehydraTECH(TM) Demonstrates Faster Delivery Of Sildenafil
March 04, 2022
Tickers
LEXX
TM
Tags
Partner Content
Market News
LEXX
From
Benzinga
Lexaria Bioscience Optimistic Of Positive Study Results
February 28, 2022
Tickers
LEXX
Tags
LEXX
Partner Content
Cannabis
From
Benzinga
Lexaria Optimistic About Expanded DehydraTECH Investigations
February 23, 2022
Tickers
LEXX
Tags
Partner Content
Market News
LEXX
From
Benzinga
Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
February 22, 2022
Tickers
LEXX
TM
Tags
Penny Stocks
Benzinga
Investor Brand Network
From
Benzinga
Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022
February 17, 2022
Tickers
LEXX
Tags
InvestorBrandNetwork
Benzinga
General
From
Benzinga
Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions
February 14, 2022
Tickers
LEXX
TM
Tags
Penny Stocks
General
News
From
Benzinga
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs
February 11, 2022
Tickers
LEXX
Tags
LEXX
Biotech
Partner Content
From
Benzinga
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders
February 09, 2022
Tickers
LEXX
Tags
Partner Content
Market News
LEXX
From
Benzinga
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study
February 03, 2022
Tickers
LEXX
Tags
Biotech
LEXX
Market News
From
Benzinga
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast
February 01, 2022
Tickers
LEXX
Tags
LEXX
Biotech
Partner Content
From
Benzinga
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
January 28, 2022
Tickers
LEXX
Tags
LEXX
Market News
Cannabis
From
Benzinga
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
January 21, 2022
Tickers
LEXX
Tags
Biotech
LEXX
Market News
From
Benzinga
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
January 19, 2022
Tickers
LEXX
Tags
General
Benzinga
LEXX
From
Benzinga
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
January 18, 2022
Tickers
LEXX
TM
Tags
InvestorBrandNetwork
Markets
Penny Stocks
From
Benzinga
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
January 12, 2022
Tickers
LEXX
Tags
Partner Content
Cannabis
Market News
From
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
January 11, 2022
Tickers
LEXX
Tags
Partner Content
Market News
LEXX
From
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today